# Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

> **NCT00391066** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 627 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** FCR + Lumiliximab
- **DRUG:** FCR

## Key facts

- **NCT ID:** NCT00391066
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2010-07
- **Final completion:** 2010-12
- **Target enrollment:** 627 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391066, "Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00391066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*